ReviewJournal of medical virology2025
Model Systems of Gammaherpesvirus Infection, Immunity, and Disease.
Review in Journal of medical virology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Integrative multi-omics analysis identifies SELL and PRF1 as key immune biomarkers and therapeutic targets in tuberculosis.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Model Systems of Gammaherpesvirus Infection, Immunity, and Disease.Journal of medical virology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Epstein-Barr virus (EBV) and Kaposi's sarcoma-associated herpesvirus (KSHV) are oncogenic human gammaherpesviruses (GHVs) associated with a broad spectrum of malignancies and chronic diseases. However, direct studies of these viruses in humans are limited by ethical constraints, technical challenges, and their strict species specificity. To overcome these barriers, researchers have developed surrogate models, with murine gammaherpesvirus 68 (MHV68) emerging as a tractable and widely utilized system. MHV68 shares key genetic and biological features with EBV and KSHV, providing critical insights into GHV pathogenesis, including viral latency, reactivation, immune evasion, and virus-host interactions. This review summarizes current cellular and animal models for GHV research, highlighting the advantages and limitations of MHV68 as a model for studying human GHVs. We explore mechanisms of viral gene function, immune modulation, and host responses, and discuss how these models have advanced our understanding of GHV-associated diseases. Improved model systems will be essential for guiding future experimental approaches and developing targeted therapies for GHV-driven malignancies and other related disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.